GRIPPOL® INFLUENZA VACCINES

GRIPPOL® PLUS
TRIVALENT VACCINE

over 14 years > 160
million doses
ГРИППОЛ® ПЛЮС

GRIPPOL®
QUADRIVALENT VACCINE

since 2018 > 2,5 million doses
ГРИППОЛ® КВАДРИВАЛЕНТ

Продолжая использование сайта, вы соглашаетесь с использованием файлов cookie. Подробнее.

AZOXIMER BROMIDE ADJUVANT

in Grippol® vaccines allows a 3-fold reduction of antigens, ensuring a pronounced and long-lasting immune response to vaccination

GRIPPOL® PLUS AND GRIPPOL® QUADRIVALENT VACCINES

meet current influenza vaccine quality standards

  • Preservative and Antibiotic-free
  • Available in individual syringe doses with an atraumatic needle
  • Manufacture in accordance with GMP standards

VACCINES GRIPPOL®

are developed with antigen-saving technology. The antigenic composition of vaccines is updated annually in accordance with the recommendations of the World Health Organization

GRIPPOL® VACCINES HAVE A MASSIVE EXPERIENCE OF USE AMONG VARIOUS CATEGORIES OF CITIZENS:

  • Children from 6 months and overе
  • Adults, elderly people, people with chronic diseases, including cardiovascular and bronchopulmonary diseases, bronchial asthma, chronic kidney disease, diabetes mellitus, allergies, and HIV infections
  • Pregnant women
The efficacy and safety
of GRIPPOL® vaccines
has been proven by clinical, post-registration, and epidemiological studies:
Grippol® with participation of
2863 children,
5181 adults
Grippol® Plus with participation of
12579 children,
9349 adults
Grippol® Quadrivalent with participation of
612 adults
440 children
Диплом лауреата Национальной премии в области импортозамещения "Приоритет-2018"
NPO Petrovax Pharm has won the Priority Pharma Award for creating and introducing Grippol® Quadrivalent, the first Russian quadrivalent influenza vaccine, into practical healthcare.
Grippol® Plus

Grippol® Plus is a trivalent influenza vaccine containing the antigens of two type A viruses and one type B virus. In addition to the antigens, it also contains azoximer bromide. It acts as an adjuvant, i.e. a substance that stimulates the immune response to antigens when the vaccine is administered, and thus contributes to its effectiveness. The addition of azoximer bromide reduces the number of antigens in the vaccine while maintaining efficacy and improving the safety profile.

Grippol® Plus contains no preservatives or antibiotics, which reduces the risk of local reactions to the vaccination. Due to these properties, Grippol® Plus is indicated for preventive vaccinations for all categories of citizens, including children over 6 months of age, pregnant women, persons with chronic diseases, the elderly, highly allergic individuals, and immunodeficient persons.

The antigenic composition of the Grippol® plus vaccine is updated annually according to WHO recommendations and forecasts of the circulation of influenza virus strains of northern hemisphere influenza season.

Grippol® Quadrivalent

Grippol® Quadrivalent is a quadrivalent vaccine that protects against two strains of type A viruses and two strains of influenza B virus (Victoria and Yamagata). Compared to trivalent vaccines, the addition of the 4th strain to the Grippol® Quadrivalent provides greater protection against influenza virus In both lines. The efficacy of flu vaccination with Grippol® Quadrivalent is due to the content of Polyoxidonium® as an adjuvant. Protecting against more strains of influenza virus, the vaccine has a high safety profile due to its reduced antigen content, as confirmed by clinical trials conducted to world standards.

Grippol® Quadrivalent is available in syringes for single individual use, and is recommended for people aged 6 to 60 with a high risk of influenza infection. These are employees of health care institutions, education and public order services, the military, social and welfare services, catering, trade services, as well as workers and engineers from all sectors of industry.

The vaccine contains no preservatives or antibiotics.

ATTENTION!

This site contains information for medical and pharmaceutical professionals. To view the content, please, confirm that you have the appropriate qualifications

Do not show this message for 30 minutes
EXIT THE SITE